From March 1988 to May 1991, 140 CarboMedics cardiac valve prostheses(75 mitral, 9 aortic and 28 double aortic-mitral) were implanted in 112 consecutive patients(mean age 36.7±11.6 years, male /female 48/76) by one surgical team operating on
adult
cardiac patients at Kyoungpook University Hospital.
Associated surgical procedures were performed in 19 patients(16.9%). Total follow up represented 2,345 patient-months(mean 22.4 months) and was 100% complete. Eighty-two Patients(73%) were in NYHA functional class III or IV preoperatively and 102
patients (95%) were in class I or II postoperatively.
Hospital (30 day)mortality was 4.4%, (3/75 mitral, 1/9 aortic, 1/28 double valve replacement) and late death was 1.7%.(1/74) mitral, 1/28 double valve replacement) The actuarial survival at 36 months was 94.0% after aortic, 92% after double valve
replacement, and 93.2% for the total group. The linearized incidence of valve related death, prosthetic valve thrombosis, anticoagulant related hemorrhage, and reoperation was 1.00%/pt-yr, 0.51%/pt-yr, and 0.51%/pt-yr respectively. The 36 month
rates or
freedom from valve replated death, thromboembolism, endocarditis, anti-coagulant related hemorrages, and reoperation were 98.75%, 100%, 99.04%, and 99.08% respectively. The 36 month rate of freedom from all valve related complications and deaths
including hospital mortality was 90.2%.
These fact suggest that the CarboMedics heart valve has excellent short-term result, low incidence of valve-related complications and valve dysfunction, and additional long term follow up study is necessary.
|